T-cell-based immunotherapy in colorectal cancer
T-cell-based immunotherapy in colorectal cancer
复制标题
基于 T 细胞的结直肠癌免疫疗法
DOI：
10.1016/j.canlet.2020.10.040
复制
发表时间：
2021-02-01
期刊：
影响因子：
9.7
通讯作者：
Zhu, Di
中科院分区：
文献类型：
--
作者：
Feng, Mei;Zhao, Zhongwei;Zhu, Di
结直肠癌(CRC)是全球癌症死亡的主要原因。结直肠癌的治疗策略包括手术切除、化疗、放射治疗等方法。然而，转移性结直肠癌患者的预后更差。近年来，基于T细胞的免疫治疗在B细胞恶性肿瘤、黑色素瘤和肺癌方面取得了良好的疗效，但大多数结直肠癌患者对免疫治疗、化疗和靶向治疗具有抵抗力。免疫检查点抑制剂在非小细胞肺癌、黑色素瘤和其他癌症中显示出令人鼓舞的结果，但免疫检查点阻断仅对具有微卫星不稳定性的CRC亚群有效。其他免疫疗法，如细胞因子、癌症疫苗、小分子、溶瘤病毒和嵌合抗原受体疗法，目前正在用于治疗结直肠癌。这篇综述分析了免疫疗法治疗结直肠癌的最新进展以及克服耐药性方面的挑战。
Colorectal cancer (CRC) is the leading cause of cancer death worldwide. CRC therapeutic strategies include surgical resection, chemotherapy, radiotherapy, and other approaches. However, patients with metastatic CRC have worse prognoses. In recent years, T-cell-based immunotherapy has elicited promising responses in B-cell malignancies, melanoma, and lung cancer, but most CRC patients are resistant to immunotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors have shown encouraging results in non-small cell lung cancer, melanoma, and other cancers, but immune checkpoint blockade is only effective for CRC subset with microsatellite instability. Other immunotherapies, such as cytokines, cancer vaccines, small molecules, oncolytic viruses, and chimeric antigen-receptor therapy, are currently in use against CRC. This review analyzes recent developments in immunotherapy for CRC treatment as well as the challenges in overcoming resistance.